✦ LIBER ✦

Report on the workshop: Von Willebrand factor and thrombotic thrombocytopenic purpura

✍ Scribed by Joel L. Moake; J. Evan Sadler; Pier Mannucci; Pankaj Ganguly

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 34 KB
Volume: 68
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.1163

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thrombotic thrombocytopenic purpura: Rec

Thrombotic thrombocytopenic purpura: Recovery after splenectomy associated with persistence of abnormally large von willebrand factor multimers

✍ Jacob M. Rowe; Charles W. Francis; Elizabeth M. Cyran; Victor J. Marder 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 1 views

Increased von Willebrand factor binding

Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura

✍ Chow, Thomas W.; Turner, Nancy A.; Chintagumpala, Murali; McPherson, Patsy D.; N 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 2 views

Extensive microvascular platelet aggregation is characteristic of thrombotic thrombocytopenic purpura (TTP). Previous studies have indicated that abnormalities of von Willebrand factor (vWf) are often present in TTP patient plasma. There has not been previously any direct evidence linking these abno

Increased von Willebrand factor (vWf) bi

Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura

✍ Joel L. Moake; Thomas W. Chow 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 2 views

Thrombotic thrombocytopenic purpura (TTP) is a disorder of systemic platelet aggregation. Evidence has accumulated that the aggregating agonist in TTP of all types is likely to be von Willebrand factor (vWf), especially unusually large vWf multimers derived from endothelial cells. Recent evidence in

Dissociation between the level of von Wi

Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura

✍ Carolyn E. Snider; Jane C. Moore; Theodore E. Warkentin; Clara N. Finch; Catheri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract Decreased von Willebrand factor (VWF)‐cleaving protease activity (<5%) has been implicated in patients with congenital thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (Upshaw‐Schulman syndrome) and associated with mutations within the __ADAMTS13__ gene. In this report, we

High titers of inhibitors of von Willebr

High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura

✍ Han-Mou Tsai 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

Rituximab for the treatment of refractor

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases

✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp